The potential therapeutic utility of GDF15-GRFAL antagonism has been demonstrated most clearly in the setting of cancer cachexia, where a blocking antibody to GDF15 prevented the cancer cachexia associated with xenograft tumors in mice (124). Here, GDF15 is linked to cancer.